Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer
Journal of Medicinal Chemistry · 13.06.2024 · 67 (11) · 8913-8931
DOI: 10.1021/acs.jmedchem.4c00196 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 29.05.2024. Verfasst von Lilan Xin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Estrogen Receptor alpha, Breast Neoplasms, Drug Resistance, Neoplasm, Cell Proliferation. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Chinese Pharmaceutical Association, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Estrogen receptor α (ERα) plays a pivotal role in the proliferation, differentiation, and migration of breast cancer (BC) cells, and aromatase (ARO) is a crucial enzyme in estrogen synthesis. Hence, it is necessary to inhibit estrogen production or the activity of ERα for the treatment of estrogen receptor-positive (ER+) BC. Herein, we present a new category of dual-targeting PROTAC degraders designed to specifically target ERα and ARO. Among them, compound 18c bifunctionally degrades and inhibits ERα/ARO, thus effectively suppressing the proliferation of MCF-7 cells while showing negligible cytotoxicity to normal cells. In vivo, 18c promotes the degradation of ERα and ARO and inhibits the growth of MCF-7 xenograft tumors. Finally, compound 18c demonstrates promising antiproliferative and ERα degradation activity against the ERαMUT cells. These findings suggest that 18c, being the inaugural dual-targeting degrader for ERα and ARO, warrants further advancement for the management of BC and the surmounting of endocrine resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- Department of Pharmacy, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- Frontier Science Center for Immunology and Metabolism, State Key Laboratory of Virology, Provincial Key Laboratory of Developmentally Originated Disease, Key Laboratory of Combinatorial Biosynthesis and Drug Discovery (…
ORCID-Profile: Hankun Hu, Chang Min, Hai-Bing Zhou
Förderung
- National Key Research and Development Program of China
- Chinese Pharmaceutical Association
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Xin, L., Wang, C., Cheng, Y., Wang, H., Guo, X., Deng, X., Deng, X., Xie, B., Hu, H., Min, C., Dong, C., & Zhou, H. B. (2024). Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer. Journal of Medicinal Chemistry, 67(11), 8913-8931. https://doi.org/10.1021/acs.jmedchem.4c00196
Vancouver
Xin L, Wang C, Cheng Y, Wang H, Guo X, Deng X, et al. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer. Journal of Medicinal Chemistry. 2024;67(11):8913-8931. doi:10.1021/acs.jmedchem.4c00196
BibTeX
@article{Xin2024,
author = {Xin, Lilan and Wang, Chao and Cheng, Yan and Wang, Hongli and Guo, Xinyi and Deng, Xiaofei and Deng, Xiangping and Xie, Baohua and Hu, Hankun and Min, Chang and Dong, Chune and Zhou, Hai-Bing},
title = {Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {11},
pages = {8913--8931},
doi = {10.1021/acs.jmedchem.4c00196}
}
EUVIMED